Unknown

Dataset Information

0

The transcription factor CUX1 negatively regulates invasion in castrate resistant prostate cancer.


ABSTRACT: Metastatic prostate cancer is treated with androgen ablation therapy but progress to castrate resistant prostate cancer (CRPC). This study aimed to investigate the role of CUX1 in CRPC using clinical samples and in vitro models. CUX1 expression was increased in androgen-independent cells compared to androgen-sensitive cells. The multi-isoform nature of CUX1 makes it difficult to assay in tissue microarrays as there is no epitope able to distinguish the many isoforms for immunohistochemistry. Using surrogate markers, we found no differential expression between castrate resistant and local hormone naïve tissue. However, differences have been demonstrated at the transcript level. In androgen-sensitive cells, migration, but not invasion, increased following CUX1 knockdown. Conversely, in androgen-independent cells, invasion was increased. This observed difference in invasion capacity is not E-cadherin mediated, as CUX1 knockdown increases the expression of E-cadherin in both cell lines with no inter-cell line difference. Cells expressed different ratios of p110/p200 isoforms depending on androgen status and cathepsin L was only detectable in androgen-sensitive cells. MMP3 is upregulated in the androgen-independent cells. Rather than a simple presence or absence of CUX1, the relative balance of CUX1 isoforms and their interplay may be a significant factor in the functional role of CUX1 in CRPC.

SUBMITTER: Dorris ER 

PROVIDER: S-EPMC7061738 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

The transcription factor CUX1 negatively regulates invasion in castrate resistant prostate cancer.

Dorris Emma R ER   O'Neill Amanda A   Treacy Ann A   Klocker Helmut H   Teltsh Omri O   Kay Elaine E   Watson R William RW  

Oncotarget 20200303 9


Metastatic prostate cancer is treated with androgen ablation therapy but progress to castrate resistant prostate cancer (CRPC). This study aimed to investigate the role of CUX1 in CRPC using clinical samples and <i>in vitro</i> models. CUX1 expression was increased in androgen-independent cells compared to androgen-sensitive cells. The multi-isoform nature of CUX1 makes it difficult to assay in tissue microarrays as there is no epitope able to distinguish the many isoforms for immunohistochemist  ...[more]

Similar Datasets

| S-EPMC3437215 | biostudies-literature
| S-EPMC4486479 | biostudies-literature
| S-EPMC4745762 | biostudies-literature
| S-EPMC5311967 | biostudies-literature
| S-EPMC5189960 | biostudies-literature
| S-EPMC3678432 | biostudies-literature
| S-EPMC4176261 | biostudies-literature
| S-EPMC4029111 | biostudies-literature
| S-EPMC3805777 | biostudies-literature
| S-EPMC3699964 | biostudies-literature